chromophobe renal cell carcinoma
play

Chromophobe Renal Cell Carcinoma TCGA KICH AWG Chairs: Chad - PowerPoint PPT Presentation

Chromophobe Renal Cell Carcinoma TCGA KICH AWG Chairs: Chad Creighton, W. Kim Rathmell Introduction Chromophobe renal cell carcinoma (ChRCC) represents ~5% of cancers arising from the kidney nephron Due in part to its relative rarity,


  1. Chromophobe Renal Cell Carcinoma TCGA KICH AWG Chairs: Chad Creighton, W. Kim Rathmell

  2. Introduction • Chromophobe renal cell carcinoma (ChRCC) represents ~5% of cancers arising from the kidney nephron • Due in part to its relative rarity, this disease has been understudied at the molecular level • Comprehensively profiled by TCGA, as the first of its Rare Tumor Projects

  3. Data summary Data Type Platforms Cases Data access Whole exome DNA sequence Illumina 66 Controlled Whole genome DNA sequence Illumina 50 Controlled Mitochondria DNA sequence Illumina (LR-PCR) 61 Controlled DNA copy number/genotype Affymetrix SNP 6 66 Controlled mRNA expression Illumina 66 Controlled - BAM files Open - expression files Illumina miRNA expression 66 Controlled - BAM files Open - expression files CpG DNA methylation Illumina 450K 66 Open 66 tumor cases for comprehensive profiling 50 cases with whole genome sequencing 61 cases with mitochondria genome sequencing

  4. Data summary Data Type Platforms Cases Data access Whole exome DNA sequence Illumina 66 Controlled Whole genome DNA sequence Illumina 50 Controlled Mitochondria DNA sequence Illumina (LR-PCR) 61 Controlled DNA copy number/genotype Affymetrix SNP 6 66 Controlled mRNA expression Illumina 66 Controlled - BAM files Open - expression files Illumina miRNA expression 66 Controlled - BAM files Open - expression files CpG DNA methylation Illumina 450K 66 Open 66 tumor cases for comprehensive profiling 50 cases with whole genome sequencing 61 cases with mitochondria genome sequencing

  5. Data summary Data Type Platforms Cases Data access Whole exome DNA sequence Illumina 66 Controlled Whole genome DNA sequence Illumina 50 Controlled Mitochondria DNA sequence Illumina (LR-PCR) 61 Controlled DNA copy number/genotype Affymetrix SNP 6 66 Controlled mRNA expression Illumina 66 Controlled - BAM files Open - expression files Illumina miRNA expression 66 Controlled - BAM files Open - expression files CpG DNA methylation Illumina 450K 66 Open 66 tumor cases for comprehensive profiling 50 cases with whole genome sequencing 61 cases with mitochondria genome sequencing

  6. Somatic alterations (copy and whole exome)

  7. DNA copy alterations CCRCC ChRCC classic eosinophilic

  8. Somatically mutated genes Frequency of mutation (%) N=66 ChRCC

  9. DNA methylation and RNA expression

  10. DNA methylation low high Widespread 64,000 differential loci in total differences between ChRCC and CCRCC Shen H Laird P normal CCRCC ChRCC

  11. Anatomy of the kidney nephron proximal distal http://en.wikipedia.org/wiki/File:Kidney_nephron_molar_transport_diagram.svg

  12. Anatomy of the kidney nephron proximal distal CCRCC? ChRCC?

  13. Gene expression atlas of the kidney nephron Published mRNA profiling dataset of micro-dissected regions (mouse and human) Cheval et al. PLOS One 2012 proximal distal

  14. ChRCC versus CCRCC expression differences reflect distal versus proximal nephron TCGA Kidney cancer CCRCC ChRCC Kidney nephron atlas proximal distal proximal distal

  15. Mitochondrial DNA alterations

  16. mtDNA somatic mutations in ChRCC Muzny D, Buhay C Wang M Red , affects protein coding Events with >50% heteroplasmy shown

  17. mtDNA Red , high in ChRCC mutations Blue , low involve the in ChRCC electron Yellow , mtDNA mutation transport chain

  18. Red , high ChRCC relies in ChRCC upon oxidative Blue , low phosphorylation in ChRCC Yellow , mtDNA mutation

  19. Red , high ChRCC relies in ChRCC upon oxidative Blue , low phosphorylation in ChRCC Yellow , mtDNA mutation

  20. Whole Genome Analysis

  21. Kataegis observed in ChRCC Davis C, Wheeler D

  22. mRNA n=50 ChRCC correlates of kataegis Creighton C, Davis C Includes TERT Cases with mRNA expression kataegis (n=3) low high

  23. TERT PM Structural breakpoints within TERT promoter n=50 ChRCC region Copy gain Copy loss Breakpoint X Davis C

  24. Structural variants associated with TERT promoter region by WGS analysis breakpoint A breakpoint B case chr:pos ori gene chr:pos ori gene event type KL-8341 5:1116986 -1 5:1296148 1 TERT PM tandem dup. KN-8435 5:272199 1 PDCD6 5:1296716 1 TERT PM inversion KM-8438 5:1348783 -1 5:1295372 1 TERT PM deletion KL-8346 5:1125430 -1 5:1295604 1 TERT PM tandem dup. KL-8323 5:49560803 1 5:1299528 -1 TERT PM tandem dup. KL-8323 5:49563017 -1 5:1297603 1 TERT PM del-insertion KM-8443 13:52688659 1 NEK5 5:1305300 1 TERT PM Inter-chr transl. Meerkat algorithm Davis C, Wang L, Park P

  25. TERT promoter-associated SVs correlate with high TERT expression TERT expression 1000 100 10 0 SV mut WT norm 6 3 57 25

  26. TERT promoter-associated SVs correlate with high TERT expression TERT expression P < 1E-20 1000 100 P = 0.01 10 0 SV mut WT norm 6 3 57 25

  27. Validation of TERT PM-associated SVs KN-8435 (inversion) normal tumor Wang M, Muzny D

  28. Validation of TERT PM-associated SVs KN-8435 (inversion) normal tumor normal tumor PI-P2 P3-P4 PI-P3 PI-P2 P3-P4 PI-P3 Wang M, Muzny D

  29. Conclusions • Comprehensive molecular analysis of a rare cancer type as a platform for discovery • Global molecular patterns may provide clues as to a cancer’s cell of origin • mtDNA sequencing incorporated into multi- platform molecular characterization of cancer • Discovery of recurrent genomic rearrangements involving TERT promoter region

  30. KICH Analysis Working Group Chad Creighton (co-chair) Baylor Lisa Henske Harvard Kimryn Rathmell (co-chair) UNC Donna Muzny Baylor Hui Shen USC Pheroze Tamboli MDACC David Kwiatkowski Harvard Ari Hakimi MSKCC Toni Chouieri Harvard James Hsieh MSKCC Caleb Davis Baylor Victor Reuter MSKCC Richard Gibbs Baylor Christopher Ricketts NIH/NCI David Wheeler Baylor W. Marston Linehan NIH/NCI Maggi Morgan Baylor Laura Schmidt NIH/NCI Larry Donehower Baylor Maria Merino NIH/NCI Preethi Gunaratne Baylor Brian Shuch NIH/NCI Gordon Robertson BCGSC Satish Tickoo MSKCC Andy Chu BCGSC Billy Kim UNC Andrew Mungall BCGSC Eric Wallen UNC Payal Sipahimalani BCGSC Angie Smith UNC Andrew Cherniack Broad Sahil Seth MDACC Matthew Meyerson Broad Catherine Fahey UNC Raju Kucherlapati Harvard Kate Hacker UNC Sabina Signoretti Harvard Gyan Bhanot Rutgers Lixing Wang Harvard Peter Laird USC Peter Park Harvard STAFF: Jean Claude Zenklusen, Ina Felau, Lindsay Lund, + NCI Senior Leadership; NHGRI Senior Leadership

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend